Support for LAist comes from
Local and national news, NPR, things to do, food recommendations and guides to Los Angeles, Orange County and the Inland Empire
Stay Connected
Listen

Share This

News

Cedars-Sinai Sees Early Promise In COVID-19 Treatment Study

A vial of the drug Remdesivir presented this week at a news conference in Germany announcing the start of a trial there. (Ulrich Perrey / AFP via Getty Images)
()

Congress has cut federal funding for public media — a $3.4 million loss for LAist. We count on readers like you to protect our nonprofit newsroom. Become a monthly member and sustain local journalism.

A small trial of an experimental antiviral drug that could treat COVID-19 patients has shown encouraging results, Cedars-Sinai Hospital officials said today.

Cedars-Sinai is among dozens of sites around the world participating in a clinical trial of the drug Remdesivir. A study about what's happened so far was published Friday in the New England Journal of Medicine.

Cedars-Sinai's director of epidemiology says definitive conclusions cannot be drawn, but results from this group of patients are hopeful.

Keep in mind the sample size is very small. There was also no control group receiving a placebo, a common practice in clinical trials.

Support for LAist comes from

According to the study, 61 patients received at least one dose of the drug but only 53 were able to be analyzed. Of those, 22 were in the U.S.

The study found 18 days after the initial dose:

  • 36 patients (68%) improved, including 17 of the 30 patients who were receiving mechanical ventilation who were extubated.
  • 25 patients (47%) were discharged
  • 7 patients (13%) died

Of the sickest patients, those receiving "invasive ventilation" the mortality rate was 18% (6 of 34). There was also one death of a patient not receiving invasive ventilation. The study's authors also reported side effects ranging from a rash and diarrhea to acute kidney injury.

Our news is free on LAist. To make sure you get our coverage: Sign up for our daily coronavirus newsletter. To support our non-profit public service journalism: Donate Now.

MORE ON CORONAVIRUS:

As Editor-in-Chief of our newsroom, I’m extremely proud of the work our top-notch journalists are doing here at LAist. We’re doing more hard-hitting watchdog journalism than ever before — powerful reporting on the economy, elections, climate and the homelessness crisis that is making a difference in your lives. At the same time, it’s never been more difficult to maintain a paywall-free, independent news source that informs, inspires, and engages everyone.

Simply put, we cannot do this essential work without your help. Federal funding for public media has been clawed back by Congress and that means LAist has lost $3.4 million in federal funding over the next two years. So we’re asking for your help. LAist has been there for you and we’re asking you to be here for us.

We rely on donations from readers like you to stay independent, which keeps our nonprofit newsroom strong and accountable to you.

No matter where you stand on the political spectrum, press freedom is at the core of keeping our nation free and fair. And as the landscape of free press changes, LAist will remain a voice you know and trust, but the amount of reader support we receive will help determine how strong of a newsroom we are going forward to cover the important news from our community.

Please take action today to support your trusted source for local news with a donation that makes sense for your budget.

Thank you for your generous support and believing in independent news.

Chip in now to fund your local journalism
A row of graphics payment types: Visa, MasterCard, Apple Pay and PayPal, and  below a lock with Secure Payment text to the right
(
LAist
)

Trending on LAist